rosiglitazone has been researched along with Aberrant Tissue in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aronson, J; Czernik, P; Huang, S; Kolli, V; Lecka-Czernik, B; Liu, L; Lu, Y; Rahman, S; Suva, LJ | 1 |
| Chai, DC; D'Hooghe, T; Fisseha, S; Lebovic, DI; Mueller, MD; Mwenda, JM; Santi, A | 1 |
2 other study(ies) available for rosiglitazone and Aberrant Tissue
| Article | Year |
|---|---|
Rosiglitazone inhibits bone regeneration and causes significant accumulation of fat at sites of new bone formation.
Topics: Adipose Tissue; Animals; Bone Diseases; Bone Regeneration; Choristoma; Down-Regulation; Drug Evaluation, Preclinical; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Osteogenesis; Rosiglitazone; Thiazolidinediones; X-Ray Microtomography | 2012 |
PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study.
Topics: Animals; Choristoma; Drug Evaluation, Preclinical; Endometriosis; Endometrium; Female; Ligands; Papio; Peritoneal Cavity; PPAR gamma; Prospective Studies; Random Allocation; Rosiglitazone; Thiazolidinediones | 2007 |